BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

Albireo gains on Phase III rare liver diseases readout Albireo Pharma Inc. (NASDAQ:ALBO) gained $12.25 (45%) to $39.62 on Tuesday after announcing odevixibat met its two primary endpoints in the Phase...
BioCentury | Dec 11, 2019
Clinical News

Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares

Iterum became the latest anti-infective developer to suffer a blow in the market, losing more than a third of its value with a narrow miss on the primary endpoint in a pivotal trial. Still, the...
BioCentury | Aug 16, 2019
Company News

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response letter this year. Nabriva...
BioCentury | Aug 6, 2019
Company News

Newly launched LUCA planning to tackle infections in women

Seed Health launched LUCA Tuesday with $2.8 million in seed funding to develop living medicines to fight infections in women. It is the first biotech to emerge from the biotherapeutics accelerator. The funding will take...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Blindness Mouse studies identified a LIF-based fusion protein that could help treat blindness. The fusion protein consists of human LIF fused to bacterial dihydrofolate reductase (DHFR), which is stabilized by the antibiotic Primsol trimethoprim....
BioCentury | Oct 18, 2018
Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A VAR2CSA-coated magnetic bead-based method for detecting circulating tumor cells (CTCs) could help diagnose prostate cancer and the stage of disease. The method consists of introducing plasma samples from patients and magnetic...
BioCentury | Aug 9, 2018
Translation in Brief

Buggy Bug World

A data dive into the TwinsUK registry based at King’s College London has revealed new associations between gut microbiota and disease, including some outside the usual suspects, like urinary incontinence. The study found not just...
BioCentury | Jul 19, 2018
Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18 Selected developments and initiatives in 2Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI) and the...
BioCentury | Jun 30, 2018
Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
Items per page:
1 - 10 of 148